These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32721416)

  • 1. Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors.
    Shock A; Humphreys D; Nimmerjahn F
    J Allergy Clin Immunol; 2020 Sep; 146(3):492-500. PubMed ID: 32721416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
    Schwab I; Nimmerjahn F
    Nat Rev Immunol; 2013 Mar; 13(3):176-89. PubMed ID: 23411799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
    Patel DD; Bussel JB
    J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases.
    Norris PAA; Kaur G; Lazarus AH
    Curr Opin Hematol; 2020 Nov; 27(6):392-398. PubMed ID: 32868670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases.
    Ruiz de Souza V; Kaveri SV; Kazatchkine MD
    Clin Exp Rheumatol; 1993; 11 Suppl 9():S33-6. PubMed ID: 8354005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases.
    Hurez V; Kaveri SV; Kazatchkine MD
    J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.
    Ahmed AR; Kaveri S
    Front Immunol; 2018; 9():1189. PubMed ID: 30072982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.
    Brückner C; Lehmann C; Dudziak D; Nimmerjahn F
    Int Immunol; 2017 Dec; 29(11):499-509. PubMed ID: 29300958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.
    Li N; Zhao M; Hilario-Vargas J; Prisayanh P; Warren S; Diaz LA; Roopenian DC; Liu Z
    J Clin Invest; 2005 Dec; 115(12):3440-50. PubMed ID: 16284651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.
    Peter HH; Ochs HD; Cunningham-Rundles C; Vinh DC; Kiessling P; Greve B; Jolles S
    J Allergy Clin Immunol; 2020 Sep; 146(3):479-491.e5. PubMed ID: 32896308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).
    Kaveri S; Prasad N; Vassilev T; Hurez V; Pashov A; Lacroix-Desmazes S; Kazatchkine M
    Mult Scler; 1997 Apr; 3(2):121-8. PubMed ID: 9291165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases.
    Bayry J; Misra N; Latry V; Prost F; Delignat S; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Transfus Clin Biol; 2003 Jun; 10(3):165-9. PubMed ID: 12798851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.
    Sesarman A; Vidarsson G; Sitaru C
    Cell Mol Life Sci; 2010 Aug; 67(15):2533-50. PubMed ID: 20217455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of intravenous immunoglobulins.
    Baerenwaldt A; Biburger M; Nimmerjahn F
    Expert Rev Clin Immunol; 2010 May; 6(3):425-34. PubMed ID: 20441428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.
    Ronda N; Hurez V; Kazatchkine MD
    Vox Sang; 1993; 64(2):65-72. PubMed ID: 8456559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins.
    Bouhlal H; Martinvalet D; Teillaud JL; Fridman C; Kazatchkine MD; Bayry J; Lacroix-Desmazes S; Kaveri SV
    J Clin Immunol; 2014 Jul; 34 Suppl 1():S4-11. PubMed ID: 24682714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of immunomodulatory action of intravenous immunoglobulin in autoimmune and systemic inflammatory diseases.
    Vassilev T; Kazatchkine MD
    Ther Apher; 1997 Feb; 1(1):38-41. PubMed ID: 10225779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FcγRIIIA (CD16) in IVIg-mediated anti-inflammatory function.
    Ben Mkaddem S; Aloulou M; Benhamou M; Monteiro RC
    J Clin Immunol; 2014 Jul; 34 Suppl 1():S46-50. PubMed ID: 24728843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.